What's in Gan & Lee Pharmaceuticals.'s pipeline?

Gan & Lee Pharmaceuticals. has 9 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with Gan & Lee Pharmaceuticals.'s portfolio?

Top competitors by shared drug class: Jiangsu HengRui Medicine Co., Ltd., Novo Nordisk A/S, Assistance Publique Hopitaux De Marseille, AstraZeneca, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gan-lee-pharmaceuticals.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Gan & Lee Pharmaceuticals. — Portfolio Competitive Intelligence Brief

Gan & Lee Pharmaceuticals. pipeline: 1 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Dupilumab Injection	Dupilumab Injection	marketed
Bempedoic Acid Tablet	Bempedoic Acid Tablet	phase 3	Uricosuric agent / Xanthine oxidase inhibitor	AMPK (AMP-activated protein kinase) / Xanthine oxidase pathway	Rheumatology / Metabolic Disease
GZR18	GZR18	phase 3	Long-acting basal insulin analog	Insulin receptor	Diabetes
Semaglutide(Wegovy® )	Semaglutide(Wegovy® )	phase 3	GLP-1 receptor agonist	GLP-1R	Diabetes

Therapeutic area mix

Diabetes · 2
Rheumatology / Metabolic Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
Novo Nordisk A/S · 2 shared drug classes
Assistance Publique Hopitaux De Marseille · 1 shared drug class
AstraZeneca · 1 shared drug class
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · 1 shared drug class
Beijing Chao Yang Hospital · 1 shared drug class
Beijing Dongfang Biotech Co., Ltd. · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gan & Lee Pharmaceuticals.:

Cite this brief

Drug Landscape (2026). Gan & Lee Pharmaceuticals. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gan-lee-pharmaceuticals. Accessed 2026-05-16.